Tessa announces autologous and allogeneic cell therapy data presentations at 2021 ASH Annual Meeting

Tessa announces autologous and allogeneic cell therapy data presentations at 2021 ASH Annual Meeting

KUALA LUMPUR, Nov 5 -- Tessa Therapeutics Ltd (Tessa), a clinical-stage cell therapy company announced that data from its ongoing autologous and allogeneic cell therapy studies targeting lymphomas has been accepted for two separate poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition held from Dec 11-14.

The presentations include clinical data from a Phase II multi-center study evaluating safety and efficacy of CD30 CAR-T therapy (TT11) in patients with relapsed / refractory classical Hodgkin Lymphoma (R/R cHL).

Also included is Phase I investigator-initiated study testing allogeneic ‘off-the-shelf’ CD30 CAR EBVST therapy (TT11X) in patients with relapsed / refractory CD30+ lymphoma.

Accepted abstracts will also be published online in the November supplemental issue of Blood, a publication of the American Society of Hematology, according to a statement.

TT11 is a CAR-T therapy, which harvests a patient’s own T-cells and modifies them by introducing a CD30-directed Chimeric Antigen Receptor (CAR) to target and kill CD30+ cells in classical Hodgkin Lymphoma (cHL).

CD30 is a well validated lymphoma target with homogeneous expression in 98 per cent of cHL and a significant proportion of subsets of non-Hodgkin Lymphomas.

Meanwhile, TT11X is an allogeneic ‘off-the-shelf’ therapy which augments Epstein bar virus-specific T-cells with CD30 CAR technology.

The therapy is based on a proprietary allogeneic cell therapy platform developed from decades-long research and development on unique properties of Virus Specific T-cells (VSTs) by Tessa’s Scientific Co-Founder, Dr Malcolm Brenner, and the team at Baylor College of Medicine.

More details at www.tessacell.com.

-- BERNAMA